Haploidentical Bone Marrow Transplantation in Sickle Cell Patients
Complete title: Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease
This is a Phase II, single arm, multi-center trial, designed to estimate the efficacy and toxicity of haploidentical bone marrow transplantation (BMT) in patients with sickle cell disease (SCD). Based on their age and entry criteria patients are stratified into two groups: (1) children with SCD with strokes; and (2) adults with severe SCD.
** For Eligibility information, please click on the "LOOK UP TRIAL AT NIH" link above. **
Other eligibility criteria may apply.
Pediatric Cancers, Miscellaneous; Sickle Cell Anemia; Anemia; Genetic Diseases, Inborn; Anemia, Hemolytic; Hematologic Diseases; Anemia, Hemolytic, Congenital; Hemoglobinopathies
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.